Enhanced ETS1 stability by DNAPKcs orchestrates transcriptional changes during chemoresistance in triple negative breast cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F25%3A00142811" target="_blank" >RIV/00216224:14110/25:00142811 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.nature.com/articles/s41523-025-00782-3" target="_blank" >https://www.nature.com/articles/s41523-025-00782-3</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41523-025-00782-3" target="_blank" >10.1038/s41523-025-00782-3</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Enhanced ETS1 stability by DNAPKcs orchestrates transcriptional changes during chemoresistance in triple negative breast cancer

Popis výsledku v původním jazyce

Triple Negative Breast Cancer (TNBC) accounts for similar to 20% of all breast cancers and results in thousands of deaths every year. The median survival of TNBC patients sharply declines with the development of chemoresistance and metastatic disease. Although high expression of ETS1 in TNBC has been associated with aggressiveness, the mechanisms of ETS1 in TNBC therapy relapse are poorly understood. Here, we show that ETS1 is responsible for driving acquired drug resistance in the TNBC cell line models resistant to 5'-Fluorouracil and doxorubicin. Protein kinase, DNAPKcs (aka PRKDC) mediated phosphorylation of ETS1 at Serine 251 residue enhances protein stability by preventing ETS1's degradation, thus enhancing ETS1-driven resistance mechanisms. Further, transcriptomic profiling of resistant cells and TNBC patients showed that phosphorylated-ETS1 could activate genes of the E2F, MYC and G2/M pathways, resulting in enhanced DNA synthesis and proliferation, leading to resistance. DNAPKcs inhibitors resulted in ETS1 degradation, inhibition of proliferation gene circuits and subsequent apoptosis in resistant TNBC cells. Phospho-S251 ETS1 and associated ETS1-driven proliferative gene signatures were observed in drug-resistant TNBC patients. Our findings suggest that DNAPKcs-mediated phosphorylation of ETS1 promotes chemoresistance in TNBC patients and can be targeted using DNAPKcs kinase inhibitors.

Název v anglickém jazyce

Enhanced ETS1 stability by DNAPKcs orchestrates transcriptional changes during chemoresistance in triple negative breast cancer

Popis výsledku anglicky

Triple Negative Breast Cancer (TNBC) accounts for similar to 20% of all breast cancers and results in thousands of deaths every year. The median survival of TNBC patients sharply declines with the development of chemoresistance and metastatic disease. Although high expression of ETS1 in TNBC has been associated with aggressiveness, the mechanisms of ETS1 in TNBC therapy relapse are poorly understood. Here, we show that ETS1 is responsible for driving acquired drug resistance in the TNBC cell line models resistant to 5'-Fluorouracil and doxorubicin. Protein kinase, DNAPKcs (aka PRKDC) mediated phosphorylation of ETS1 at Serine 251 residue enhances protein stability by preventing ETS1's degradation, thus enhancing ETS1-driven resistance mechanisms. Further, transcriptomic profiling of resistant cells and TNBC patients showed that phosphorylated-ETS1 could activate genes of the E2F, MYC and G2/M pathways, resulting in enhanced DNA synthesis and proliferation, leading to resistance. DNAPKcs inhibitors resulted in ETS1 degradation, inhibition of proliferation gene circuits and subsequent apoptosis in resistant TNBC cells. Phospho-S251 ETS1 and associated ETS1-driven proliferative gene signatures were observed in drug-resistant TNBC patients. Our findings suggest that DNAPKcs-mediated phosphorylation of ETS1 promotes chemoresistance in TNBC patients and can be targeted using DNAPKcs kinase inhibitors.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

NPJ BREAST CANCER

ISSN

2374-4677

e-ISSN

2374-4677

Svazek periodika

11

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

15

Strana od-do

1-15

Kód UT WoS článku

001603317100002

EID výsledku v databázi Scopus

2-s2.0-105019769414